Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fatty acids & cardiovascular function

This article was originally published in The Tan Sheet

Executive Summary

Consumption of EPA or DHA may reduce risk of adverse cardiovascular events by increasing systemic arterial compliance (SAC) and lowering total vascular resistance, according to study by Paul Nestel, Baker Medical Research Institute, Melbourne, Australia, et al., in August's American Journal of Clinical Nutrition. Researchers randomized 38 dyslipidemic subjects to receive either 3 g EPA/day, 3 g DHA/day or placebo for seven weeks. Primary endpoints measured were arterial functions, while secondary endpoints consisted of plasma lipid and plasma fatty acid levels. EPA group experienced 36% increase in SAC, which reflects arterial elasticity, while the DHA group saw a 27% increase. Test material was supplied by Hoffmann-La Roche and encapsulated by RP Scherer...

You may also be interested in...

US FDA Needs Plan For Addressing Inspection Backlog Post-COVID, GAO Says

Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.

Health And Wellness Trademark Review 2 March, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

In Order Shutting Down New York Supplement Firm, Federal Judge Also Criticizes FDA’s Calculations

Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts